FINWIRES · TerminalLIVE
FINWIRES

Koei Tecmo's Profit Jumps 14% in Fiscal Year 2025

By

Koei Tecmo's (TYO:3635) profit attributable to owners of the parent increased 14% to 42.8 billion yen for the fiscal year 2025 from 37.6 billion yen a year earlier.

The amusement and video game company's earnings per share increased to 131.67 yen from 113.65 yen a year ago, according to a Tokyo bourse filing on Monday.

Net sales climbed 6.3% to 88.4 billion yen for the full year ended March 31 from 83.2 billion yen in the prior year.

In a separate disclosure, Koei Tecmo raised its final dividend to 66 yen per share, from 43 yen forecasted earlier, payable from June 19.

For the fiscal year 2026, the company expects attributable profit of 31 billion yen, basic EPS of 95.38 yen, and net sales of 90 billion yen.

Koei Tecmo plans to pay a year-end dividend of 48 yen per share for the year, which is lower than the amount paid the previous year.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA